Involvement of Dihydroceramide Desaturase in Cell Cycle Progression in Human Neuroblastoma Cells

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2007 Feb 7

PMID 17283068

Citations 96

Authors

Jacqueline M Kraveka

Li Li

Zdzislaw M Szulc

Jacek Bielawski

Besim Ogretmen

Yusuf A Hannun

Lina M Obeid

Alicja Bielawska

Affiliations

Soon will be listed here.

Abstract

The role of dihydroceramide desaturase as a key enzyme in the de novo pathway of ceramide generation was investigated in human neuroblastoma cells (SMS-KCNR). A novel assay using water-soluble analogs of dihydroceramide, dihydroceramidoids (D-erythro-dhCCPS analogs), was used to measure desaturase activity in situ. Conversion of D-erythro-2-N-[12'-(1''-pyridinium)-dodecanoyl]-4,5-dihydrosphingosine bromide (C(12)-dhCCPS) to its 4,5-desaturated counterpart, D-erythro-2-N-[12'-(1''-pyridinium)dodecanoyl]sphingosine bromide (C(12)-CCPS), was determined by liquid chromatography/mass spectrometry analysis. The validity of the assay was confirmed using C(8)-cyclopropenylceramide, a competitive inhibitor of dihydroceramide desaturase. A human homolog (DEGS-1) of the Drosophila melanogaster des-1 gene was recently identified and reported to have desaturase activity. Transfection of SMS-KCNR cells with small interfering RNA to DEGS-1 significantly blocked the conversion of C(12)-dhCCPS to C(12)-CCPS. The associated accumulation of endogenous dihydroceramides confirmed DEGS-1 as the main active dihydroceramide desaturase in these cells. The partial loss of DEGS-1 inhibited cell growth, with cell cycle arrest at G(0)/G(1). This was accompanied by a significant decrease in the amount of phosphorylated retinoblastoma protein. This hypophosphorylation was inhibited by tautomycin and not by okadaic acid, suggesting the involvement of protein phosphatase 1. Additionally, we found that treatment of SMS-KCNR cells with fenretinide inhibited desaturase activity in a dose-dependent manner. An increase in dihydroceramides (but not ceramides) paralleled this process as measured by liquid chromatography/mass spectrometry. There were no effects on the mRNA or protein levels of DEGS-1, suggesting that fenretinide acts at the post-translational level as an inhibitor of this enzyme. Tautomycin was also able to block the hypophosphorylation of the retinoblastoma protein observed upon fenretinide treatment. These findings suggest a novel biological function for dihydroceramides.

Citing Articles

Bioactive Compounds Targeting Dihydroceramide and Their Therapeutic Potential in Cancer Treatment.

Jang Y Cancers (Basel). 2025; 17(5).

PMID: 40075756 PMC: 11898591. DOI: 10.3390/cancers17050909.

The Role of Vitamin E Isoforms and Metabolites in Cancer Prevention: Mechanistic Insights into Sphingolipid Metabolism Modulation.

Jang Y, Kim C Nutrients. 2024; 16(23).

PMID: 39683509 PMC: 11644559. DOI: 10.3390/nu16234115.

Antiproliferative and Morphological Effects of Fenretinide Lipid Nanosystems in Colon Adenocarcinoma Cells.

Anconelli L, Farioli F, Lodeserto P, Andreadi A, Borsetti F, Voltattorni M Pharmaceutics. 2024; 16(11).

PMID: 39598544 PMC: 11597870. DOI: 10.3390/pharmaceutics16111421.

Preclinical evaluation of fenretinide against primary and metastatic intestinal type‑gastric cancer.

Ortiz N, Diaz C Oncol Lett. 2024; 28(6):561.

PMID: 39372665 PMC: 11450695. DOI: 10.3892/ol.2024.14694.

Endogenous small molecule effectors in GATA transcription factor mechanisms governing biological and pathological processes.

Liao R, Bresnick E Exp Hematol. 2024; 137:104252.

PMID: 38876253 PMC: 11381147. DOI: 10.1016/j.exphem.2024.104252.

References

Kishikawa K, Chalfant C, Perry D, Bielawska A, Hannun Y . Phosphatidic acid is a potent and selective inhibitor of protein phosphatase 1 and an inhibitor of ceramide-mediated responses. J Biol Chem. 1999; 274(30):21335-41. DOI: 10.1074/jbc.274.30.21335. View

Geeraert L, Mannaerts G, Van Veldhoven P . Conversion of dihydroceramide into ceramide: involvement of a desaturase. Biochem J. 1997; 327 ( Pt 1):125-32. PMC: 1218771. DOI: 10.1042/bj3270125. View

Seville L, Shah N, Westwell A, Chan W . Modulation of pRB/E2F functions in the regulation of cell cycle and in cancer. Curr Cancer Drug Targets. 2005; 5(3):159-70. DOI: 10.2174/1568009053765816. View

Schulz A, Mousallem T, Venkataramani M, Persaud-Sawin D, Zucker A, Luberto C . The CLN9 protein, a regulator of dihydroceramide synthase. J Biol Chem. 2005; 281(5):2784-94. DOI: 10.1074/jbc.M509483200. View

Bielawski J, Szulc Z, Hannun Y, Bielawska A . Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods. 2006; 39(2):82-91. DOI: 10.1016/j.ymeth.2006.05.004. View

Szulc Z, Bielawski J, Gracz H, Gustilo M, Mayroo N, Hannun Y . Tailoring structure-function and targeting properties of ceramides by site-specific cationization. Bioorg Med Chem. 2006; 14(21):7083-104. DOI: 10.1016/j.bmc.2006.07.016. View

Schulze H, Michel C, van Echten-Deckert G . Dihydroceramide desaturase. Methods Enzymol. 1999; 311:22-30. DOI: 10.1016/s0076-6879(00)11063-8. View

Hannun Y, Luberto C . Ceramide in the eukaryotic stress response. Trends Cell Biol. 2000; 10(2):73-80. DOI: 10.1016/s0962-8924(99)01694-3. View

Tamrakar S, Rubin E, Ludlow J . Role of pRB dephosphorylation in cell cycle regulation. Front Biosci. 2000; 5:D121-37. DOI: 10.2741/tamrakar. View

10.

Causeret C, Geeraert L, van der Hoeven G, Mannaerts G, Van Veldhoven P . Further characterization of rat dihydroceramide desaturase: tissue distribution, subcellular localization, and substrate specificity. Lipids. 2000; 35(10):1117-25. DOI: 10.1007/s11745-000-0627-6. View

11.

Lee J, Bielawska A, Obeid L . Regulation of cyclin-dependent kinase 2 activity by ceramide. Exp Cell Res. 2000; 261(2):303-11. DOI: 10.1006/excr.2000.5028. View

12.

Sugiki H, Hozumi Y, Maeshima H, Katagata Y, Mitsuhashi Y, Kondo S . C2-ceramide induces apoptosis in a human squamous cell carcinoma cell line. Br J Dermatol. 2000; 143(6):1154-63. DOI: 10.1046/j.1365-2133.2000.03882.x. View

13.

Wang H, Maurer B, Reynolds C, Cabot M . N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase. Cancer Res. 2001; 61(13):5102-5. View

14.

Ogretmen B, Schady D, Usta J, Wood R, Kraveka J, Luberto C . Role of ceramide in mediating the inhibition of telomerase activity in A549 human lung adenocarcinoma cells. J Biol Chem. 2001; 276(27):24901-10. DOI: 10.1074/jbc.M100314200. View

15.

Wu J, DiPietrantonio A, Hsieh T . Mechanism of fenretinide (4-HPR)-induced cell death. Apoptosis. 2001; 6(5):377-88. DOI: 10.1023/a:1011342220621. View

16.

Ahn E, Schroeder J . Sphingoid bases and ceramide induce apoptosis in HT-29 and HCT-116 human colon cancer cells. Exp Biol Med (Maywood). 2002; 227(5):345-53. DOI: 10.1177/153537020222700507. View

17.

Ternes P, Franke S, Zahringer U, Sperling P, Heinz E . Identification and characterization of a sphingolipid delta 4-desaturase family. J Biol Chem. 2002; 277(28):25512-8. DOI: 10.1074/jbc.M202947200. View

18.

Hannun Y, Obeid L . The Ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J Biol Chem. 2002; 277(29):25847-50. DOI: 10.1074/jbc.R200008200. View

19.

Lovat P, Oliverio S, Ranalli M, Corazzari M, Rodolfo C, Bernassola F . GADD153 and 12-lipoxygenase mediate fenretinide-induced apoptosis of neuroblastoma. Cancer Res. 2002; 62(18):5158-67. View

20.

Kraveka J, Li L, Bielawski J, Obeid L, Ogretmen B . Involvement of endogenous ceramide in the inhibition of telomerase activity and induction of morphologic differentiation in response to all-trans-retinoic acid in human neuroblastoma cells. Arch Biochem Biophys. 2003; 419(2):110-9. DOI: 10.1016/j.abb.2003.08.034. View